Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …

Abstract Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is
predominantly located in the nucleolus and exerts multiple functions, including regulation of …

Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby
restoring normal tissue function,–. The interaction of menin with lysine methyltransferase 2A …

Abstract Treatment with Menin inhibitor (MI) disrupts the interaction between Menin and
MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of …

Acute myeloid leukemia (AML) with rearrangement of the lysine methyltransferase 2a gene
(KMT2Ar) has adverse outcomes. However, reports on the prognostic impact of various …

Despite FDA approval of nine new drugs for patients with acute myeloid leukemia (AML) in
the United States over the last 4 years, AML remains a major area of unmet medical need …

Menin inhibitors constitute a novel class of agents targeting the underlying biology of
nucleophosmin (NPM1) mutant and KMT2A (formerly known as MLL1) rearranged (KMT2Ar) …

Abstract Mutations in Nucleophosmin 1 (NPM1) are associated with a favorable prognosis in
newly diagnosed acute myeloid leukemia (AML), however, their prognostic impact in …

Highlights•AML is a highly heterogeneous disease and warrants an individualized
approach.•The advent of effective low-intensity regimens has improved outcomes in older …

Monotherapy with Menin inhibitor (MI), eg, SNDX-5613, induces clinical remissions in
patients with relapsed/refractory AML harboring MLL1-r or mtNPM1, but most patients either …